The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy

Classification by RECIP 1.0. with TRAQinform IQ technology, which was used to conduct lesion region-of-interest–based analyses at baseline and end-of-treatment PET. Regions of interest were matched across time points and categorized as new, increasing, stable, decreasing, or disappeared on basis of changes in total lesion PSMA. (A) A 67-y-old man with mCRPC treated with 4 cycles of PSMA RPT between baseline and end-of-treatment PSMA PET. Patient had new lesions, 512.7% increase in tumor volume, and 547.6% increase in PSA and was classified as having progressive disease based on RECIP 1.0. Patient had date of last follow-up of 6.3 mo from end-of-treatment PSMA PET. (B) A 73-y-old man with mCRPC treated with 6 cycles of PSMA RPT between baseline and end-of-treatment PSMA PET. Patient had no new lesions, 87.3% decrease in tumor volume, and 95.9% decrease in PSA and was classified as having partial response based on RECIP 1.0. Patient had date of last follow-up of 14.9 mo from end-of-treatment PSMA PET. (C) A 69-y-old man with mCRPC treated with 4 cycles of PSMA RPT between baseline and end-of-treatment PSMA PET. Patient had no new lesions, 3.3% increase in tumor volume, and 55.2% increase in PSA and was classified as having stable disease based on RECIP 1.0. Patient had OS of 44.3 mo from end-of-treatment PSMA PET.